COVID-19 Antibody Seroconversion in Cancer Patients: Impact of Therapy Cessation-A Single-Center Study

Overview

Journal Vaccines (Basel)

Date 2023 Nov 25

PMID 38005991

Authors

Lina Souan

Hikmat Abdel-Razeq

Sura Nashwan

Sara Al Badr

Kamal Alrabi

Maher A Sughayer

Affiliations

Soon will be listed here.

Abstract

Background: The effective development of COVID-19 vaccination has mitigated its harm. Using two laboratory methods, we investigated the efficacy of the BNT162b2 mRNA and BBIBP-CorV COVID-19 vaccines on seroconversion rates in cancer patients undergoing active cancer treatment.

Methods: SARS-CoV-2 vaccines were scheduled for 134 individuals. The consenting participants submitted three venous blood samples. Three samples: T0, T1, and T2. The ABBOTT-SARS-CoV-2 IgG II Quant and Elecsys Anti-SARS-CoV-2 assays were used to evaluate the samples and convert the antibody titers to WHO (BAU)/mL units.

Results: Cancer patients exhibited a higher seroconversion rate at T2, regardless of vaccination type, and the mean antibody titers at T1 and T2 were higher than those at T0. BBIBP-CorV patients required a booster because BNT162b2 showed a higher seroconversion rate between T0 and T1. Statistics indicate that comparing Abbott and Roche quantitative antibody results without considering the sample collection time is inaccurate.

Conclusions: COVID-19 vaccines can still induce a humoral immune response in patients undergoing cancer-targeted therapy. The strength of this study is the long-term monitoring of antibody levels after vaccination in cancer patients on active therapy using two different immunoassays. Further multicenter studies with a larger number of patients are required to validate these findings.

Citing Articles

Enhanced RBD-Specific Antibody Responses and SARS-CoV-2-Relevant T-Cell Activity in Healthcare Workers Following Booster Vaccination.

Souan L, Abdel-Razeq H, Sughayer M Curr Issues Mol Biol. 2024; 46(10):11124-11135.

PMID: 39451540 PMC: 11506206. DOI: 10.3390/cimb46100660.

References

Muller L, Kannenberg J, Biemann R, Honemann M, Ackermann G, Jassoy C . Comparison of the measured values of quantitative SARS-CoV-2 spike antibody assays. J Clin Virol. 2022; 155:105269. PMC: 9388276. DOI: 10.1016/j.jcv.2022.105269. View

Trougakos I, Terpos E, Zirou C, Sklirou A, Apostolakou F, Gumeni S . Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Med. 2021; 19(1):208. PMC: 8380479. DOI: 10.1186/s12916-021-02090-6. View

Yarza R, Bover M, Paredes D, Lopez-Lopez F, Jara-Casas D, Castelo-Loureiro A . SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer. 2020; 135:242-250. PMC: 7275164. DOI: 10.1016/j.ejca.2020.06.001. View

Ferrari D, Clementi N, Criscuolo E, Ambrosi A, Corea F, Di Resta C . Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine. Vaccines (Basel). 2021; 9(11). PMC: 8620373. DOI: 10.3390/vaccines9111357. View

Jung K, Shin S, Nam M, Hong Y, Roh E, Park K . Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls. J Clin Lab Anal. 2021; 35(9):e23921. PMC: 8418513. DOI: 10.1002/jcla.23921. View

Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A . Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020; 117(21):11727-11734. PMC: 7260975. DOI: 10.1073/pnas.2003138117. View

Liang W, Guan W, Chen R, Wang W, Li J, Xu K . Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21(3):335-337. PMC: 7159000. DOI: 10.1016/S1470-2045(20)30096-6. View

Lukaszuk K, Kiewisz J, Rozanska K, Dabrowska M, Podolak A, Jakiel G . Usefulness of IVD Kits for the Assessment of SARS-CoV-2 Antibodies to Evaluate the Humoral Response to Vaccination. Vaccines (Basel). 2021; 9(8). PMC: 8402409. DOI: 10.3390/vaccines9080840. View

Pinana J, Vazquez L, Calabuig M, Lopez-Corral L, Martin-Martin G, Villalon L . One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. Blood Cancer J. 2023; 13(1):8. PMC: 9812742. DOI: 10.1038/s41408-022-00778-3. View

10.

Mascellino M, Di Timoteo F, De Angelis M, Oliva A . Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infect Drug Resist. 2021; 14:3459-3476. PMC: 8418359. DOI: 10.2147/IDR.S315727. View

11.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

12.

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z . Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020; 10(6):783-791. PMC: 7309152. DOI: 10.1158/2159-8290.CD-20-0422. View

13.

Waldhorn I, Holland R, Goshen-Lago T, Shirman Y, Szwarcwort-Cohen M, Reiner-Benaim A . Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. Cancer Discov. 2021; 11(10):2430-2435. DOI: 10.1158/2159-8290.CD-21-1072. View

14.

Kreuzberger N, Hirsch C, Andreas M, Bohm L, Brockelmann P, Di Cristanziano V . Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. Cochrane Database Syst Rev. 2022; 8:CD015021. PMC: 9361430. DOI: 10.1002/14651858.CD015021. View

15.

Mason P, Rizzuto R, Iannelli L, Baccaglini F, Rizzolo V, Baraldo A . Comparison of Adverse Effects of Two SARS-CoV-2 Vaccines Administered in Workers of the University of Padova. Vaccines (Basel). 2023; 11(5). PMC: 10221025. DOI: 10.3390/vaccines11050951. View

16.

Di Noia V, Pimpinelli F, Renna D, Barberi V, Maccallini M, Gariazzo L . Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution. Clin Cancer Res. 2021; 27(24):6815-6823. DOI: 10.1158/1078-0432.CCR-21-2439. View

17.

Leyfman Y, Emmanuel N, Menon G, Joshi M, Wilkerson W, Cappelli J . Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients. J Hematol Oncol. 2023; 16(1):39. PMC: 10100631. DOI: 10.1186/s13045-023-01432-6. View

18.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

19.

Corti C, Crimini E, Tarantino P, Pravettoni G, Eggermont A, Delaloge S . SARS-CoV-2 vaccines for cancer patients: a call to action. Eur J Cancer. 2021; 148:316-327. PMC: 7904467. DOI: 10.1016/j.ejca.2021.01.046. View

20.

Mariano G, Farthing R, Lale-Farjat S, Bergeron J . Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. Front Mol Biosci. 2021; 7:605236. PMC: 7773825. DOI: 10.3389/fmolb.2020.605236. View